Nanogen and Spectral announce cardiac test agreement

Dec. 21, 2005 — Nanogen Inc. of San Diego and Spectral Diagnostics Inc. of Toronto announced the signing of a definitive agreement whereby Nanogen will acquire Spectral’s rapid cardiac immunoassay test business, including the cardiac STATus, Decision Point and i-Lynx product lines.

Nanogen will assume related sales, marketing and manufacturing activities. The transaction is expected to close during the first quarter of 2006 and is subject to approval by Spectral’s shareholders and other standard closing conditions.

The total amount of the transaction is $10.54 million, comprised of $6.62 million in cash and $3.92 million in Nanogen common shares.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.